#1EXACT SCIENCES EXACT SCIENCES We aim to help eradicate cancer by preventing it, detecting it earlier, and guiding its treatment. 1#2Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; expectations for development of new or improved products and services and their impact on patients; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts. Risks and uncertainties that could adversely affect the Company's business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation, those described in the filings made by the company with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based. In addition to the company's financial results determined in accordance with U.S. GAAP, the company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management uses non-GAAP financial measures to establish budgets, manage the Company's business, and set incentive and compensation arrangements. The company presents EBITDA, adjusted EBITDA, non-GAAP gross margin, non-GAAP gross profit, core revenue, and free cash flow. Please refer to the appendix accompanying this presentation for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures. EXACT SCIENCES 2#3Source: Centers for Disease Control and Prevention EXACT SCIENCES #1 cancer is the #1 cause of death under age 85 3#4#5#6Cologuard® is having a meaningful impact and becoming more deeply ingrained in clinical practice []™ 13 million completed tests. Source: Exact Sciences data EXACT SCIENCES 2015 2016 2017 Cumulative completed Cologuard tests 13M 2018 2019 2020 2021 2022 2023 6#7A new standard in non-invasive screening EXACT SCIENCES next-generation cologuard® Specificity including no findings Specificity including non-advanced findings Cancer sensitivity Curable-stage cancer sensitivity High-grade dysplasia sensitivity Advanced precancer sensitivity BLUE-C (n=20,176) 91% 93% 94% 93% 75% 43% DeeP-C (n=9,989) 87% 90% 92% 93% 69% 42% Source: Imperiale TF et al., ACG conference abstract (2023); Imperiale TF et al., N Engl J Med (2014); curable-stage cancer includes stages I to III; for specificity definitions, please refer to next-generation Cologuard top-line results press release issued June 20, 2023 7#8#9#10The Exact Sciences platform enables sustainable revenue growth and profitability improvement over time EXACT SCIENCES Drive profitable revenue Ĉ Provide a seamless experience for customers C Invest in world-class talent dedicated to fighting cancer EXACT SCIENCES Increase access & drive adoption Offer tests that impact decision-making 2 Generate rock-solid clinical evidence 10#11The driving force behind our flywheel is our team 6,500 teammates dedicated to defeating cancer 54% gender diversity 40+ locations globally STE Source: Exact Sciences internal data EXACT SCIENCES VACT Invest in world-class talent Drive profitable revenue Provide seamless customer experience Offer tests that impact decision-making 2 Generate rock-solid clinical evidence ✓ Increase access & drive adoption Great Place To Work® Certified MAY 2023-MAY 2024 USA TM Forbes Best-in-State Employer 11#12Advancing our pipeline of life-changing tests Colorectal cancer screening (CRC) 110M people in U.S. Multi-cancer early detection (MCED) 135M people in U.S. Molecular residual disease (MRD) 12M annual U.S. testing opportunities Source: U.S. Census data, Exact Sciences estimates; includes U.S. markets only EXACT SCIENCES [ cancerguard™ oncodetect™ Drive profitable revenue Ĉ next-generation cologuard® Invest in world-class talent Provide seamless customer experience Offer tests that impact decision-making 2 Generate rock-solid clinical evidence ✓ Increase access & drive adoption 12#13Generate rock-solid clinical evidence The NEW ENGLAND JOURNAL of MEDICINE ESTABLISHED IN 1812 APRIL 3, 2014 Multitarget Stool DNA Testing for Colorectal-Cancer Screening Thomas F. Imperiale, M.D., David F. Ransohoff, M.D., Steven H. Itzkowitz, M.D., Theodore R. Levin, M.D., Philip Lavin, Ph.D., Graham P. Lidgard, Ph.D., David A. Ahlquist, M.D., and Barry M. Berger, M.D. ABSTRACT BACKGROUND An accurate, noninvasive test could improve the effectiveness of colorectal-cancer From the Department of Medicine, Indi screening. ana University School of Medicine, the Regenstrief Institute, the Simon Cancer Center, and the Center for Innovation at Roudebush Veterans Affairs Medical METHODS Departments of Medicine and Epidemi- We compared a noninvasive, multitarget stool DNA test with a fecal immunochem-Center-all in Indianapolis (T.F.I.); the ical test (FIT) in persons at average risk for colorectal cancer. The DNA test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 meth- ylation, and B-actin, plus a hemoglobin immunoassay. Results were generated with the use of a logistic-regression algorithm, with values of 183 or more considered to be positive. FIT values of more than 100 ng of hemoglobin per milliliter of buffer were considered to be positive. Tests were processed independently of colonoscopic findings. ology and the Lineberger Comprehensive Cancer Center, University of North Caro- lina at Chapel Hill, Chapel Hill (D.F.R.); the Dr. Henry D. Janowitz Division of Gastro- enterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York (S.H.I.): Kaiser Permanente Medical Center, Walnut Creek, CA (T.R.L.); Boston Biostatistics Research Founds- tion, Framingham MA (PL); Exact Sci- ences, Madison, WI (G.PL, B.M.B.); and the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN (D.A.A.). Address reprint requests to Dr. Imperiale at Indiana University Medical Center Regenstrief Institute, 1050 Wis- hard Blvd., Indianapolis, IN 46202 VOL. 370 NO. 14 RESULTS Of the 9989 participants who could be evaluated, 65 (0.7%) had colorectal cancer and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile serrated polyps measuring 21 cm in the greatest dimension) on colonoscopy. The sensitivity for detecting colorectal cancer was 92.3% with DNA testing and 73.8% with FIT (P=0.002). The sensitivity for detecting advanced precancerous lesions was 42.4% with DNA testing and 23.8% with FIT (P<0.001). The rate of detection of polyps with high-grade dysplasia was 69.2% with DNA testing and 46.2% with FIT (P=0.004); the rates of detection of serrated sessile polyps measuring 1 cm or more were 42.4% and 5.1%, respectively (P<0.001). Specificities with DNA testing and FIT DOI: 10.1056/NEJMoa1311194 were 86.6% and 94.9%, respectively, among participants with nonadvanced or neg-2014 Marche Melical Society ative findings (P<0.001) and 89.8 % and 96.4%, respectively, among those with N Engl J Med 2014;370128797 negative results on colonoscopy (P<0.001). The numbers of persons who would need to be screened to detect one cancer were 154 with colonoscopy, 166 with DNA testing, and 208 with FIT. EXACT SCIENCES CONCLUSIONS In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results. (Funded by Exact Sciences; ClinicalTrials.gov number, NCT01397747.) This article was published on March 19, 2014, at NEJM.org. The NEW ENGLAND JOURNAL ESTABLISHED IN 1812 of MEDICINE JULY 12, 2018 Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer J.A. Sparano, R.J. Gray, D.F. Makower, K.I. Pritchard, K.S. Albain, D.F. Hayes, C.E. Geyer, Jr., E.C. Dees, M.P. Goetz, J.A. Olson, Jr., T. Lively, S.S. Badve, T.J. Saphner, L.I. Wagner, T.J. Whelan, M.J. Ellis, S. Paik, W.C. Wood, P.M. Ravdin, M.M. Keane, H.L. Gomez Moreno, P.S. Reddy, T.F. Goggins, L.A. Mayer, A.M. Brufsky, D.L. Toppmeyer, V.G. Kaklamani, J.L. Berenberg, J. Abrams, and G.W. Sledge, Jr. ABSTRACT BACKGROUND The recurrence score based on the 21-gene breast cancer assay predicts chemother- apy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy for most patients, who have a midrange score. METHODS We performed a prospective trial involving 10,273 women with hormone-recep tor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary node-negative breast cancer. Of the 9719 eligible patients with follow-up informa- tion, 6711 (69%) had a midrange recurrence score of 11 to 25 and were randomly assigned to receive either chemoendocrine therapy or endocrine therapy alone. The trial was designed to show noninferiority of endocrine therapy alone for invasive disease-free survival (defined as freedom from invasive disease recurrence, second primary cancer, or death). VOL. 379 NO. 2 RESULTS Endocrine therapy was noninferior to chemoendocrine therapy in the analysis of invasive disease-free survival (hazard ratio for invasive disease recurrence, second primary cancer, or death (endocrine vs. chemoendocrine therapy), 1.08; 95% con- fidence interval, 0.94 to 1.24; P=0.26). At 9 years, the two treatment groups had similar rates of invasive disease-free survival (83.3% in the endocrine-therapy group and 84.3% in the chemoendocrine-therapy group), freedom from disease recurrence at a distant site (94.5% and 95.0%) or at a distant or local-regional site (92.2% and 92.9%), and overall survival (93.9% and 93.8%). The chemotherapy benefit for in- vasive disease-free survival varied with the combination of recurrence score and age (P=0.004), with some benefit of chemotherapy found in women 50 years of age or younger with a recurrence score of 16 to 25. CONCLUSIONS Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor-positive, HER2-negative, axillary node-negative breast cancer who had a midrange 21-gene recurrence score, although some benefit of chemotherapy was found in some women 50 years of age or younger. (Funded by the National Cancer Institute and others; TAILORX ClinicalTrials.gov number, NCT00310180) The authors' full names, academic de- grees, and affiliations are listed in the Ap pendix. Address reprint requests to Dr.. Sparano at Montefiore Medical Center, 1695 Eastchester Rd., Bronx, NY 10461, or at [email protected]. A full list of the investigators in this trial is provided in the Supplementary Appen dix, available at NEJM.org. This article was published on June 3, 2018, at NEJM.org. N Engl J Med 2018,379:111-21. DOI: 10.1056/NEJMoa1804710 Copyright © 2018 M Medical Society Drive profitable revenue Ĉ Invest in world-class talent Provide seamless customer experience 6 New England Journal of Medicine publications 115+ publications and abstracts presented in 2023 Offer tests that impact decision-making 2 Generate rock-solid clinical evidence Increase access & drive adoption 13#141.6M+ FIELD CALLS EACH YEAR cologuard® EXACT SCIENCES oncotype DXⓇ Source: Exact Sciences internal data oncoExTra TM Invest in world-class talent Drive profitable revenue Provide seamless customer experience Offer tests that impact decision-making Į Generate rock-solid clinical evidence Increase access & drive adoption 1,200 person commercial team 1,000 person primary care team 200 person global Precision Oncology team 14#15Provide a seamless experience for customers 8:35 EXACT SCIENCES Hi, Selena! [cologuard Your kit was deliver Collect your sample Your test result will be availabl you and your ordering provide within 2 weeks. To view, log in. create an Exact Sciences acco EXACT SCIENCES Collect sample → Return kit → More FAQ → 8:35 EXACT SCIENCES STEP 1 Check the kit 200 Check to make sure you have parts of the kit. Unpack your kit Check the items in yo and make sure you ha following: . Bracket .Sample container Tube • Bottle of liquid (preservative) Sample labels all 8:35 EXACT SCIENCES SHIPPING Return your kit two ways Plan to collect your sample when you can get it back to UPS the same or next day. Remember, some locations are closed on Sundays or holidays. ** all Schedule UPS pickup → Drop off at UPS → EVAC SCIENCES Source: Exact Sciences internal data Invest in world-class talent Drive profitable revenue Provide seamless customer experience Offer tests that impact decision-making Į Generate rock-solid clinical evidence ✓ Increase access & drive adoption 15M+ patient calls each year 75%+ enabled by technology 15#16Drive profitable revenue Core revenue grew 23% in 3Q23 Core revenue $506M +23% $625M Screening revenue 3Q23 $361M +31% $472M $145M Drive profitable revenue Ĉ Invest in world-class talent Provide seamless customer experience -+5%* Offer tests that impact decision-making 2 Precision Oncology core revenue 3Q22 3Q22 3Q23 3Q22 Please refer to the appendix accompanying this presentation for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures EXACT SCIENCES Increase access & drive adoption Generate rock-solid clinical evidence ✓ $153M 3Q23 16#17#18#19#20#21#22#23